Advances in CAR-T immunotherapy

Advances in CAR-T Immunotherapy

Edited by: Profs. Marko Radic, Djordje Atanackovic and Tim Luetkens
In-house Editors: Drs. Linda Gummlich and Akila Sridhar

Chimeric antigen receptor (CAR) T cells therapies, as a novel modality in cancer immunotherapy, provide a quantum leap in the treatment of cancer.  In recognition of the new advances that the CAR approach represents in hematological malignancies, the Food and Drug Administration (FDA) approved two separate cell-based gene therapies, one from Novartis (Kamryah) the other from Gilead (Yescarta), for treatment of B cell leukemias.  These concrete steps that advance the CAR therapy into the clinic, providing the backdrop and motivation to assist the integration of the CAR-T immunotherapy into the standard treatment modalities of cancer.  We envision that accelerated progress with clinical trials of CAR-T cells, the proper dosing of engineered T cells along with optimized GMP-compliant production of patient-derived T lymphocytes, combination therapies using CAR-T cells and additional chemo- and immune-therapies, and increased safety considerations with diminished side-effects will remain the focus of scientific investigations.  

Acknowledging this leap in science, from the lab to the clinic, BMC Cancer and BMC Biotechnology, present the recent advances in the development, applications and safety of CAR-T immunotherapy in this collection.

1. Colorectal cysts as a validating tool for CAR therapy

   Treatment of cancers has largely benefited from the development of immunotherapy. In particular, Chimeric Antigen Receptor (CAR) redirected T cells have demonstrated impressive efficacy against B-cell malignan...

   Authors:Pierre Dillard, Maren Lie, Elizabeth Baken, Viola Hélène Lobert, Emmanuelle Benard, Hakan Köksal, Else Marit Inderberg and Sébastien Wälchli

   Citation:BMC Biotechnology 2020 20:30

   Content type:Methodology article

    

   Published on: 1 June 2020

   • ViewFull Text
    
   • ViewPDF

2. Downregulation of S100 calcium binding protein A12 inhibits the growth of glioma cells

   S100 calcium binding protein A12 (S100A12) is a member of the S100 protein family and is widely expressed in neutrophil and low expressed in lymphocytes and monocyte. However, the role of S100A12 in glioma has...

   Authors:Chunhe Lu, Jia Liu, Mingze Yao, Lun Li and Guangyu Li

   Citation:BMC Cancer 2020 20:261

   Content type:Research article

    

   Published on: 30 March 2020

   • ViewFull Text
    
   • ViewPDF

3. Impact of [64Cu][Cu(ATSM)] PET/CT in the evaluation of hypoxia in a patient with Glioblastoma: a case report

   Glioblastoma multiform (GBM), a malignant brain tumour, has a very often poor prognosis. The therapeutic approach is represented by surgery followed by radiotherapy and chemotherapy. Hypoxia is a factor that c...

   Authors:Vincenzo Gangemi, Chiara Mignogna, Giusy Guzzi, Angelo Lavano, Salvatore Bongarzone, Giuseppe Lucio Cascini and Umberto Sabatini

   Citation:BMC Cancer 2019 19:1197

   Content type:Case report

    

   Published on: 6 December 2019

   • ViewFull Text
    
   • ViewPDF

4. Tuning the performance of CAR T cell immunotherapies

   Simultaneous advances in gene editing, T cell engineering and biotechnology currently provide an opportunity for rapid progress in medicine. The approval of chimeric antigen receptor (CAR) T cell therapies by ...

   Authors:Noah H. Richardson, Jordan B. Luttrell, Jonathan S. Bryant, Damian Chamberlain, Saleem Khawaja, Indira Neeli and Marko Radic

   Citation:BMC Biotechnology 2019 19:84

   Content type:Review

    

   Published on: 29 November 2019

   • ViewFull Text
    
   • ViewPDF

5. A gene expression-based study on immune cell subtypes and glioma prognosis

   Glioma is a common malignant tumours in the central nervous system (CNS), that exhibits high morbidity, a low cure rate, and a high recurrence rate. Currently, immune cells are increasingly known to play roles...

   Authors:Qiu-Yue Zhong, Er-Xi Fan, Guang-Yong Feng, Qi-Ying Chen, Xiao-Xia Gou, Guo-Jun Yue and Gui-hai Zhang

   Citation:BMC Cancer 2019 19:1116

   Content type:Database

    

   Published on: 15 November 2019

   • ViewFull Text
    
   • ViewPDF

6. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing

   Chimeric antigen receptor (CAR)-based T cell therapy is in early clinical trials to target the neuroectodermal tumor, neuroblastoma. No preclinical or clinical efficacy data are available for retinoblastoma to...

   Authors:Lena Andersch, Josefine Radke, Anika Klaus, Silke Schwiebert, Annika Winkler, Elisa Schumann, Laura Grunewald, Felix Zirngibl, Carina Flemmig, Michael C. Jensen, Claudia Rossig, Antonia Joussen, Anton Henssen, Angelika Eggert, Johannes H. Schulte and Annette Künkele

   Citation:BMC Cancer 2019 19:895

   Content type:Research article

    

   Published on: 9 September 2019

   • ViewFull Text
    
   • ViewPDF

7. Modulation of chimeric antigen receptor surface expression by a small molecule switch

   Engineered therapeutic cells have attracted a great deal of interest due to their potential applications in treating a wide range of diseases, including cancer and autoimmunity. Chimeric antigen receptor (CAR)...

   Authors:Alexandre Juillerat, Diane Tkach, Brian W. Busser, Sonal Temburni, Julien Valton, Aymeric Duclert, Laurent Poirot, Stéphane Depil and Philippe Duchateau

   Citation:BMC Biotechnology 2019 19:44

   Content type:Research article

    

   Published on: 3 July 2019

   • ViewFull Text
    
   • ViewPDF

8. A survivin-responsive, conditionally replicating adenovirus induces potent cytocidal effects in adult T-cell leukemia/lymphoma

   Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell malignancy caused by long-term human T-cell leukemia virus type I (HTLV-1) infection. Survivin-responsive, conditionally replicating adenoviruses reg...

   Authors:Shinsuke Suzuki, Hiroki Kofune, Kimiharu Uozumi, Makoto Yoshimitsu, Naomichi Arima, Kenji Ishitsuka, Shin-ichi Ueno and Ken-ichiro Kosai

   Citation:BMC Cancer 2019 19:516

   Content type:Research article

    

   Published on: 29 May 2019

   • ViewFull Text
    
   • ViewPDF

9. Challenges of driving CD30-directed CAR-T cells to the clinic

   Chimeric antigen receptor T (CAR-T) cells are a promising new treatment for patients with relapsed or refractory hematologic malignancies, including lymphoma. Given the success of CAR-T cells directed against ...

   Authors:Natalie S. Grover and Barbara Savoldo

   Citation:BMC Cancer 2019 19:203

   Content type:Review

    

   Published on: 6 March 2019

   • ViewFull Text
    
   • ViewPDF

10. Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer

    Salivary gland cancers are not sensitive to conventional radiotherapy or chemotherapy regimens. Therefore, the development of a new treatment strategy is of critical importance for improving the prognosis. We ...

    Authors:Yuji Makita, Naoki Kunii, Daiju Sakurai, Fumie Ihara, Shinichiro Motohashi, Akane Suzuki, Toshinori Nakayama and Yoshitaka Okamoto

    Citation:BMC Cancer 2018 18:1254

    Content type:Research article

     

    Published on: 17 December 2018

    • ViewFull Text
     
    • ViewPDF

11. CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report

    Adults with relapsed acute lymphoblastic leukemia (ALL) have a poor prognosis, especially in patients who relapsed within 6 months of complete remission 1 (CR1). Allogeneic hematopoietic stem cell transplantat...

    Authors:Shupeng Wen, Zhiyun Niu, Lina Xing, Ying Wang, Hang Li, Na Kuang, Jianmin Luo, Xuejun Zhang and Fuxu Wang

    Citation:BMC Cancer 2018 18:1143

    Content type:Case report

     

    Published on: 20 November 2018

    • ViewFull Text
     
    • ViewPDF

12. The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis

    Chimeric antigen receptor T (CAR T) cells immunotherapy is rapidly developed in treating cancers, especially relapsed or refractory B-cell malignancies.

    Authors:Hui Zhou, Yuling Luo, Sha Zhu, Xi Wang, Yunuo Zhao, Xuejin Ou, Tao Zhang and Xuelei Ma

    Citation:BMC Cancer 2018 18:929

    Content type:Research article

     

    Published on: 26 September 2018

    • ViewFull Text
     
    • ViewPDF

13. Optimized DNA electroporation for primary human T cell engineering

    Effective gene-delivery systems for primary human T cell engineering are useful tools for both basic research and clinical immunotherapy applications. Pseudovirus-based systems and electro-transfection are the...

    Authors:Zhang Zhang, Shunfang Qiu, Xiaopeng Zhang and Wei Chen

    Citation:BMC Biotechnology 2018 18:4

    Content type:Methodology article

     

    Published on: 30 January 2018

    • ViewFull Text
     
    • ViewPDF

14. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma

    Adoptive T-cell therapy relying on conventional T cells transduced with T-cell receptors (TCRs) or chimeric antigen receptors (CARs) has caused substantial tumor regression in several clinical trials. However,...

    Authors:Dennis C. Harrer, Bianca Simon, Shin-ichiro Fujii, Kanako Shimizu, Ugur Uslu, Gerold Schuler, Kerstin F. Gerer, Stefanie Hoyer, Jan Dörrie and Niels Schaft

    Citation:BMC Cancer 2017 17:551

    Content type:Research article

     

    Published on: 17 August 2017

    • ViewFull Text
     
    • ViewPDF

15. Overview of methodologies for T-cell receptor repertoire analysis

    The T-cell receptor (TCR), located on the surface of T cells, is responsible for the recognition of the antigen-major histocompatibility complex, leading to the initiation of an inflammatory response. Analysin...

    Authors:Elisa Rosati, C Marie Dowds, Evaggelia Liaskou, Eva Kristine Klemsdal Henriksen, Tom H Karlsen and Andre Franke

    Citation:BMC Biotechnology 2017 17:61

    Content type:Methodology article

     

    Published on: 10 July 2017

    • ViewFull Text
     
    • ViewPDF

16. Challenges in the translation and commercialization of cell therapies

    Cell therapies are an emerging form of healthcare that offer significant potential to improve the practice of medicine and provide benefits to patients who currently have limited or no treatment options. Ideal...

    Authors:Brittany P. Dodson and Aaron D. Levine

    Citation:BMC Biotechnology 2015 15:70

    Content type:Research article

     

    Published on: 7 August 2015

    • ViewFull Text
     
    • ViewPDF

17. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice

    Adoptive transfer of T cells genetically engineered with a chimeric antigen receptor (CAR) has successfully been used to treat both chronic and acute lymphocytic leukemia as well as other hematological cancers...

    Authors:Victoria Hillerdal, Mohanraj Ramachandran, Justyna Leja and Magnus Essand

    Citation:BMC Cancer 2014 14:30

    Content type:Research article

     

    Published on: 18 January 2014

    • ViewFull Text
     
    • ViewPDF